Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature
Oral Oncology , 08/02/2012
Rabinowits G et al. – Epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of the tumors, and it is correlated with poor response to treatment and worse outcome. Multiple therapies targeting this pathway have been tested. Cetuximab is the only EGFR inhibitor approved in HNSCC, but response rates are low.